For Health Care Professionals Outside the US
Find a Centre
Find a Centre

REVOLUTIONISING THE Treatment OF CD19-EXPRESSING B-CELL MALIGNANCIES1

KYMRIAH is the the first approved CAR-T therapy to utilise the 4-1BB costimulatory domain
  • An adoptive, immunocellular therapy that contains reprogrammed autologous T cells that express a chimeric antigen receptor (CAR) targeting cancerous (and other) B-cells
Watch to see how KYMRIAH works





KYMRIAH UTILISES THE 4-1BB DOMAIN TO SUPPORT expansion and durable persistence1

  • Specifically designed to enhance early T-cell expansion and long-term endurance of CAR-T cells2,3
  • Demonstrated induction of central memory T-cell differentiation for enduring protection and immunosurveillance in vitro3
  • May help KYMRIAH CAR-T cells evade some of the body’s native immunosuppressive stimuli4
NEXT: Treatment
References:
  1. Kymriah Summary of Product Characteristics. Novartis Pharma AG; 2022.
  2. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453-1464.
  3. Kawalekar OU, O’Connor RS, Fraietta JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(2):380-390.
  4. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. doi:10.1126/scitranslmed.3002842.

You are now leaving KYMRIAH.com and will be redirected to Novartis.com to review the press release.

Cancel
Continue